Remedy publishes financial information quarterly as business reviews of Q1 and Q3, half-year review of Q1–Q2, and a full-year review.

Financial targets

In the long term, the company’s aim is to create profitable growth by expanding the product portfolio and entering into new partnerships with its clients. The aim is for the growth to mainly take place organically. In terms of finances, the company is on a stable foundation.

Dividend policy

Remedy’s Board of Directors has established a dividend policy aimed at maximizing ownership value through efficient allocation of capital.

The payment of any dividend is influenced by business investment needs, expected return on investments and ensuring liquidity. In the event that dividend is paid, all shares of the company are entitled to equal dividend.

Key figures

FAS (AUDITED) 2020 2019 2018 2017 2016
Revenue, 1 000 € 41,086 31,645 20,146 17,168 16,414
Growth in revenue, % 29.8% 57.1% 17.3% 4.6% 19.4%
Operating profit (EBIT), 1 000 € 13,245 6,534 0,609 2,006 3,946
Operating profit, % of revenue 32.2% 20.6% 3.0% 11.7% 24.0%
Result for the period under review, 1 000 € 10,337 5,238 0,532 1,469 3,166
Result for the period under review, % of revenue 25.2% 16.6% 2.6% 8.6% 19.3%
Balance sheet total, 1 000 € 48,355 35,896 28,261 26,652 11,190
Net cash, 1 000 € 20,016 15,876 20,089 20,694 10,348
Net gearing, % -56.6% -60.2% -89.9% -94.8% -137.3%
Equity ratio, % 73.2% 73.5% 79.1% 81.9% 74.1%
Number of personnel on average during the period under review 265 228 169 139 123*

* The method for calculating the average number of personnel has changed since the 2016 financial year, and the comparable figure is 128.